Spyre Therapeutics (SYRE) Stock Forecast & Price Target

$30.23

+1.27 (+4.39%)

(As of 02:38 PM ET)

Spyre Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 10 Analyst Ratings

Based on 10 Wall Street analysts who have issued ratings for Spyre Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 10 have given a buy rating for SYRE.

Consensus Price Target

$43.43
43.66% Upside

High Forecast	$54.00
Average Forecast	$43.43
Low Forecast	$31.00

According to the 10 analysts' twelve-month price targets for Spyre Therapeutics, the average price target is $43.43. The highest price target for SYRE is $54.00, while the lowest price target for SYRE is $31.00. The average price target represents a forecasted upside of 43.66% from the current price of $30.23.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Buy	Buy	Buy	N/A
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	10 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$43.43	$43.17	$43.17	N/A
Forecasted Upside	43.66% Upside	38.16% Upside	38.16% Upside	N/A

Trump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absolute (Ad)

Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.

This means you must act NOW before it's too late.

SYRE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYRE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Spyre Therapeutics Stock vs. The Competition

Type	Spyre Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	49.96% Upside	1,006.91% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/4/2024	Wedbush 3 of 5 stars		Initiated Coverage	Outperform	$45.00	+69.17%
7/16/2024	Evercore ISI 2 of 5 stars	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/13/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$35.00 ➝ $40.00	+5.62%
5/10/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$32.00 ➝ $40.00	+5.18%
5/2/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$50.00	+47.62%
3/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$36.00 ➝ $54.00	+40.33%
12/11/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$44.00	+124.38%
12/11/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$31.00	+58.08%
12/4/2023	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Slutsky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
11/29/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:05 PM ET.

SYRE Forecast - Frequently Asked Questions

What is Spyre Therapeutics' forecast for 2024?: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Spyre Therapeutics is $43.43, with a high forecast of $54.00 and a low forecast of $31.00.
Should I buy or sell Spyre Therapeutics stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spyre Therapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRE shares.
Does Spyre Therapeutics's stock price have much upside?: According to analysts, Spyre Therapeutics's stock has a predicted upside of 42.01% based on their 12-month stock forecasts.
What analysts cover Spyre Therapeutics?: Spyre Therapeutics has been rated by research analysts at Evercore ISI, and Wedbush in the past 90 days.
Do Wall Street analysts like Spyre Therapeutics more than its competitors?: Analysts like Spyre Therapeutics more than other "medical" companies. The consensus rating for Spyre Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SYRE compares to other companies.